IP Library Granted Patent US 11,078,220
Granted Patent B2
US 11,078,220 · App. 16/864,510 · Granted Aug 3, 2021

High-purity large-scale preparation of stannsoporfin

Inventors: George S. Drummond (New York, NY); Robert Caroselli (East Brunswick, NJ); Keith A. Cooke (Milton, CA); Daniel Levin (Toronto, CA); David G. Roe (Rockwood, CA); Christopher P. Boucher (Newmarket, CA)
Assignee: Mallinckrodt Hospital Products IP Limited
C07F7/2284A61K9/0019A61K31/555C07D487/22C07F7/003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,078,220
App. No.
16/864,510
Granted
Aug 3, 2021
Kind
B2
Abstract

Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.

Claims (20)

1. A composition comprising stannsoporfin, wherein the stannsoporfin is at least about 97% pure, and wherein any individual impurity is present in an amount less than about 0.08%, the stannsoporfin formed by: a) contacting a solution or suspension of tin (II) oxide with a mesoporphyrin IX or salt thereof under conditions suitable to form a crude stannsoporfin; and b) purifying the crude stannsoporfin to form the stannsoporfin.

2. The composition of claim 1 , wherein the composition comprises palladium in an amount of less than about 20 ppm.

3. The composition of claim 1 , wherein the composition comprises palladium in an amount of less than about 10 ppm.

4. The composition of claim 1 , wherein the composition comprises at least about 10 grams of stannsoporfin.

5. The composition of claim 1 , wherein the composition comprises at least about 100 grams of stannsoporfin.

6. The composition of claim 1 , wherein the stannsoporfin is a single-batch preparation of stannsoporfin.

7. The composition of claim 1 , wherein the stannsoporfin is at least about 98.5% pure.

8. The composition of claim 1 , wherein any impurity present is present in an amount of about 0.07% or less.

9. The composition of claim 1 , wherein the purifying the crude stannsoporfin comprises a hot acid trituration, followed by treatment at high pH at or above pH 9 followed by re-acidification, and subsequent hot acid trituration.

10. The composition of claim 1 , wherein the mesoporphyrin IX of salt thereof is formed by contacting hemin with a pre-hydrogenated catalyst.

11. The composition of claim 10 , wherein the pre-hydrogenated catalyst is formed by exposing a metallic hydrogenation catalyst to a hydrogen atmosphere.

12. The composition of claim 1 , wherein the mesoporphyrin IX or salt thereof comprises mesoporphyrin IX dihydrochloride.

13. The composition of claim 1 , wherein the composition further comprises at least one impurity in an amount between about 0.05% and about 0.08%, the at least one impurity having a relative retention time of 0.72-0.73 in an HPLC analysis.

14. A composition comprising stannsoporfin, wherein the stannsoporfin is at least about 97% pure, and wherein any individual impurity is present in an amount less than about 0.08%, the stannsoporfin formed by: a) exposing a metallic hydrogenation catalyst to a hydrogen atmosphere to form a pre-hydrogenated catalyst; b) contacting hemin with the pre-hydrogenated catalyst to form a mesoporphyrin IX or salt thereof; c) contacting a solution or suspension of tin (II) oxide with the mesoporphyrin IX or salt thereof under conditions suitable to form a crude stannsoporfin; and d) purifying the crude stannsoporfin via hot acid trituration, followed by treatment at high pH at or above pH 9 followed by re-acidification, and subsequent hot acid trituration to form the stannsoporfin.

15. The composition of claim 14 , wherein the metallic hydrogenation catalyst comprises palladium on carbon.

16. The composition of claim 14 , wherein the mesoporphyrin IX or salt thereof comprises mesoporphyrin IX dihydrochloride.

17. The composition of claim 14 , wherein the composition comprises palladium in an amount of less than about 20 ppm.

18. The composition of claim 14 , wherein the composition comprises palladium in an amount of less than about 10 ppm.

19. The composition of claim 14 , wherein the composition comprises at least about 10 grams of stannsoporfin.

20. The composition of claim 14 , wherein the stannsoporfin is at least about 98.5% pure.

Assignments (10)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: SPECGX LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2020
From: INFACARE PHARMACEUTICAL CORPORATION
To: MALLINCKRODT PHARMA IP TRADING D.A.C.
Reel/Frame 052627/0104 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2020
From: DRUMMOND, GEORGE S.; CAROSELLI, ROBERT; COOKE, KEITH A.; LEVIN, DANIEL; ROE, DAVID G.; BOUCHER, CHRISTOPHER P.
To: INFACARE PHARMACEUTICAL CORPORATION
Reel/Frame 052628/0146 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2020
From: MALLINCKRODT IP UNLIMITED COMPANY
To: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
Reel/Frame 052627/0370 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2020
From: MALLINCKRODT PHARMA IP TRADING D.A.C.
To: MALLINCKRODT IP UNLIMITED COMPANY
Reel/Frame 052627/0253 →
Continuity (11)
Continuation 16298603 · Mar 11, 2019
Continuation 15867900 · Jan 11, 2018
Division 15343967 · Nov 4, 2016
Continuation 14793921 · Jul 8, 2015
Continuation 14460080 · Aug 14, 2014
Continuation 14019513 · Sep 5, 2013
Continuation 12968651 · Dec 15, 2010
Continuation 11867559 · Oct 4, 2007
Provisional Application 60904601 · Feb 28, 2007
Provisional Application 60849641 · Oct 4, 2006
Related Publication 20200255458A1 · Aug 13, 2020